Hyper-Sensitive? Targeted Therapy With a Primed Immune System

Affiliations

¹ Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
² Department of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia, Canada.
³ Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: cho@bccancer.bc.ca.

Free article

Editorial

Rebekah Rittberg et al. J Thorac Oncol. 2022 Jun.

Free article

. 2022 Jun;17(6):734-736.

doi: 10.1016/j.jtho.2022.03.003.

¹ Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
² Department of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia, Canada.
³ Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: cho@bccancer.bc.ca.

No abstract available

Comment on

Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001.
McCoach CE, Rolfo C, Drilon A, Lacouture M, Besse B, Goto K, Zhu VW, Tan DSW, Farajian S, Potter LA, Kherani JF, Soldatenkova V, Olek EA, Muehlenbein CE, Park K. McCoach CE, et al. J Thorac Oncol. 2022 Jun;17(6):768-778. doi: 10.1016/j.jtho.2022.02.004. Epub 2022 Feb 17. J Thorac Oncol. 2022. PMID: 35183775 Free PMC article.